|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Recombinant Mouse ASGPR1 / ASGR1 protein (Catalog#50083-M07H)|
|0.2 μm filtered solution in PBS with 5% trehalose|
|Produced in rabbits immunized with purified, recombinant Mouse ASGPR1 / ASGR1 (rM ASGPR1 / ASGR1; Catalog#50083-M07H; NP_033844.1; Ser 60-Asn 284). ASGPR1 / ASGR1 specific IgG was purified by Mouse ASGPR1 / ASGR1 affinity chromatography.|
|Mouse ASGPR1 / ASGR1|
|WB, ELISA, IHC-P, IP|
WB: 10-50 μg/mL
ELISA: 0.5-1.0 μg/mL
This antibody can be used at 0.5-1.0 μg/mL with the appropriate secondary reagents to detect Mouse ASGR1. The detection limit for Mouse ASGR1 is 0.00245 ng/well.
IHC-P: 0.1-2 μg/mL
IP: 1-4 μg/mg of lysate
|This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.|
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
The asialoglycoprotein receptor (ASGPR), an endocytotic cell surface receptor expressed by hepatocytes, is triggered by triantennary binding to galactose residues of macromolecules such as asialoorosomucoid (ASOR). ASGPR belongs to the long-form subfamily of the C-type/Ca2+ dependent lectin family. It is a complex of two noncovalently-linked and highly homologous subunits, a major 42 kDa glycoprotein ASGPR1(MHL-1) and a minor 51 kDa glycoprotein ASGR2 (MHL-2). ASGPR1 is synthesized as a type II transmembrane protein that contains a cytosolic N-terminal domain, a single transmembrane segment, and an extracellular domain which contains two important structural regions. The first is a stalk domain that contributes to noncovalent oligomerization, and the second is a Ca2+-dependent carbohydrate binding domain at the very C-terminus that is unusually stabilized by three ions. The research regarded that ASGPR1 could be targeted for anti- hepatitis B virus (HBV) drug development.